CA2867456A1 - Combination therapies including inhibitors of the extracellular domain of e-cadherin - Google Patents

Combination therapies including inhibitors of the extracellular domain of e-cadherin Download PDF

Info

Publication number
CA2867456A1
CA2867456A1 CA2867456A CA2867456A CA2867456A1 CA 2867456 A1 CA2867456 A1 CA 2867456A1 CA 2867456 A CA2867456 A CA 2867456A CA 2867456 A CA2867456 A CA 2867456A CA 2867456 A1 CA2867456 A1 CA 2867456A1
Authority
CA
Canada
Prior art keywords
secad
agent
cadherin
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2867456A
Other languages
English (en)
French (fr)
Inventor
Sabine Brouxhon
Stephanos Kyrkanides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CA2867456A1 publication Critical patent/CA2867456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2867456A 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin Abandoned CA2867456A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611390P 2012-03-15 2012-03-15
US61/611,390 2012-03-15
US201261736475P 2012-12-12 2012-12-12
US61/736,475 2012-12-12
PCT/US2013/032656 WO2013138790A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Publications (1)

Publication Number Publication Date
CA2867456A1 true CA2867456A1 (en) 2013-09-19

Family

ID=49161879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867456A Abandoned CA2867456A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Country Status (8)

Country Link
US (2) US20150037354A1 (https=)
EP (1) EP2844270A4 (https=)
JP (1) JP2015514062A (https=)
KR (1) KR20140138956A (https=)
CN (1) CN104519899A (https=)
CA (1) CA2867456A1 (https=)
RU (1) RU2014141114A (https=)
WO (1) WO2013138790A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043633A1 (en) * 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US10000479B2 (en) 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use
KR102486321B1 (ko) * 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
CN115040695B (zh) * 2021-03-09 2023-10-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414097B (de) * 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
US8455249B2 (en) * 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
EP2632489B1 (en) * 2010-10-27 2020-01-15 The Research Foundation for The State University of New York Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Also Published As

Publication number Publication date
KR20140138956A (ko) 2014-12-04
US20150037354A1 (en) 2015-02-05
CN104519899A (zh) 2015-04-15
JP2015514062A (ja) 2015-05-18
EP2844270A4 (en) 2016-01-27
US20190008957A1 (en) 2019-01-10
EP2844270A1 (en) 2015-03-11
WO2013138790A1 (en) 2013-09-19
RU2014141114A (ru) 2016-05-10

Similar Documents

Publication Publication Date Title
US20190008957A1 (en) Combination therapies including inhibitors of the extracellular domain of e-cadherin
US20210380671A1 (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
CN110546277B (zh) 用于癌症的诊断和治疗方法
JP2021001176A (ja) Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法
HK1204950A1 (en) Binding agents that modulate the hippo pathway and uses thereof
JP2018529719A (ja) Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
CN113196061A (zh) 肉瘤样肾癌的诊断和治疗方法
KR20230053686A (ko) Egfr 돌연변이를 갖는 비소세포 폐암의 치료
KR20230025691A (ko) 삼중 음성 유방암을 치료하기 위한 방법과 조성물
JP2017502025A (ja) 肉腫を治療するための組成物および方法
AU2013231846A1 (en) Combination therapies including inhibitors of the extracellular domain of E-cadherin
US20190218302A1 (en) Anti-cancer combination treatment
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
HK40094175A (zh) 使用grem1拮抗剂治疗疾病的方法
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr
HK1194681A (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
HK40053242A (en) Diagnostic and therapeutic methods for sarcomatoid kidney cancer
HK40018953A (en) Diagnostic and therapeutic methods for cancer
HK40018953B (zh) 用於癌症的诊断和治疗方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190315